Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
evifacotrep
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Evifacotrep (BMS-986410) is a small molecule inhibitor of the transient receptor potential canonical 4 and 5 (TRPC4/5) ion channels. Developed by Bristol Myers Squibb, it is currently in Phase 1 clinical development for the treatment of mood and anxiety disorders, including major depressive disorder (MDD). TRPC4 and TRPC5 are non-selective cation channels expressed in brain regions associated with emotional processing, such as the amygdala and hippocampus. By inhibiting these channels, evifacotrep aims to modulate neuronal excitability and provide therapeutic benefit in psychiatric conditions where TRPC4/5 overactivity or signaling is implicated.
- Other names
- TRPC4/5 Inhibitor
02
Targets
TRPC4 (Transient receptor potential cation channel subfamily C member 4)TRPC5 (Transient receptor potential Canonical-5)
Beyond the preview
Go deeper on evifacotrep.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on evifacotrep.